MK8353 (Synonyms: SCH900353) |
| Catalog No.GC18156 |
Selective and orally available ERK1/2 inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1184173-73-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MK-8353 is a potent, selective and orally available ERK1/2 inhibitor. It is a clinical candidate suitable for twice daily oral dosing as a potential new cancer therapeutic.
MK-8353 demonstrates kinase selectivity over a 227-human kinase panel; no additional kinase in the panel was inhibited by more than 35% at the 0.1 μM concentration, and only 3 kinases (CLK2, FLT4, and Aurora B) were inhibited >50% at the 1.0 μM concentration. MK-8353 shows potent antitumor activity against various cancer cell lines, such Malme-3M cells (Melanoma), Colo-205 cells (Colon), NCI-H292 cells (Lung), A-549 cells (NSCLC), 8505C cells (Thyroid), SW-626 cells (Ovarian), with EC50s of 21 nM, 19 nM, 130 nM, 230 nM, 210 nM, 108 nM.
MK-8353 administered by oral gavage at 60 mg/kg twice daily results in at least 50% tumor growth inhibition or regression in 83% of the animal models (including LOX, Colo-205, MIA PaCa-2, and Calu-6 cells).
References
1. Moschos SJ, et al. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018 Feb 22;3(4). pii: 92352.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *